New data show noninferiority of efficacy for subcutaneous formulation of CTP13 biosimilar infliximab to intravenous formulation of CTP13 in people with rheumatoid arthritis

The results after switching from intravenous IV to subcutaneous SC treatment at Week 30 were comparable with that of maintaining CTP13 SC up to Week 54 up to Week 64 for safety profile1The study showed CTP13 SC achieved a sustained mean serum concentration...